메뉴 건너뛰기




Volumn 57, Issue 102-103, 2010, Pages 1272-1278

Pilot study of systemic combination therapy with S-1, an oral fluoropyrimidine, and cisplatin for hepatocellular carcinoma with extrahepatic metastases

Author keywords

Cisplatin; Extrahepatic metastases; Hepatocellular carcinoma; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; INTERFERON;

EID: 79251567081     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (4)

References (42)
  • 2
    • 33646568784 scopus 로고    scopus 로고
    • Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world
    • Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24:2137-2150.
    • (2006) J Clin Oncol , vol.24 , pp. 2137-2150
    • Kamangar, F.1    Dores, G.M.2    Anderson, W.F.3
  • 3
    • 33645286738 scopus 로고    scopus 로고
    • Management of hepatocellular carcinoma in Japan
    • Okita K: Management of hepatocellular carcinoma in Japan. J Gastroenterol 2006; 41:100-106.
    • (2006) J Gastroenterol , vol.41 , pp. 100-106
    • Okita, K.1
  • 4
    • 0036754637 scopus 로고    scopus 로고
    • Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma
    • DOI 10.1016/S0002-9610(02)00933-9, PII S0002961002009339
    • Kamada K, Kitamoto M, Aikata H, et al: Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma. Am J Surg 2002; 184:284-290. (Pubitemid 35279301)
    • (2002) American Journal of Surgery , vol.184 , Issue.3 , pp. 284-290
    • Kamada, K.1    Kitamoto, M.2    Aikata, H.3    Kawakami, Y.4    Kono, H.5    Imamura, M.6    Nakanishi, T.7    Chayama, K.8
  • 5
    • 0036237822 scopus 로고    scopus 로고
    • Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
    • Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164-1171
    • (2002) Hepatology , vol.35 , pp. 1164-1171
    • Lo, C.M.1    Ngan, H.2    Tso, W.K.3
  • 6
    • 0029745063 scopus 로고    scopus 로고
    • Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer
    • Rossi S, Di Stasi M, Buscarini E, et al: Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol 1996; 167:759-768.
    • (1996) AJR Am J Roentgenol , vol.167 , pp. 759-768
    • Rossi, S.1    Di Stasi, M.2    Buscarini, E.3
  • 7
    • 0033556688 scopus 로고    scopus 로고
    • Combined transcatheter arterial chemoembolization and local radio-therapy of unresectable hepatocellular carcinoma
    • Seong J, Keum KC, Han KH, et al: Combined transcatheter arterial chemoembolization and local radio-therapy of unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 1999; 43:393-397.
    • (1999) Int J Radiat Oncol Biol Phys , vol.43 , pp. 393-397
    • Seong, J.1    Keum, K.C.2    Han, K.H.3
  • 8
    • 0028270011 scopus 로고
    • Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system
    • Iwamiya T, Sawada S, Ohta Y: Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Cancer Chemother Pharmacol 1994; 33 Suppl:S134-138.
    • (1994) Cancer Chemother Pharmacol , vol.33 , Issue.SUPPL.
    • Iwamiya, T.1    Sawada, S.2    Ohta, Y.3
  • 9
    • 0141743490 scopus 로고    scopus 로고
    • Radiofrequency ablation in the treatment of small hepatocellular carcinomas: Comparison of the radiofrequency effect with and without chemoembolization
    • Kitamoto M, Imagawa M, Yamada H, et al: Radiofrequency ablation in the treatment of small hepatocellular carcinomas: comparison of the radiofrequency effect with and without chemoembolization. AJR Am J Roentgenol 2003; 181:997-1003.
    • (2003) AJR Am J Roentgenol , vol.181 , pp. 997-1003
    • Kitamoto, M.1    Imagawa, M.2    Yamada, H.3
  • 10
    • 67650725801 scopus 로고    scopus 로고
    • Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma
    • Kawaoka T, Aikata H, Takaki S, et al: Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Cardiovasc Intervent Radiol 2009; 32:687-694.
    • (2009) Cardiovasc Intervent Radiol , vol.32 , pp. 687-694
    • Kawaoka, T.1    Aikata, H.2    Takaki, S.3
  • 11
    • 0032898237 scopus 로고    scopus 로고
    • Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials
    • Llovet JM, Bustamante J, Castells A, et al: Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29:62-67.
    • (1999) Hepatology , vol.29 , pp. 62-67
    • Llovet, J.M.1    Bustamante, J.2    Castells, A.3
  • 13
    • 0031782818 scopus 로고    scopus 로고
    • A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients: The Cancer of the Liver Italian Program (CLIP) investigators
    • A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28:751-755.
    • (1998) Hepatology , vol.28 , pp. 751-755
  • 14
    • 33846630414 scopus 로고    scopus 로고
    • Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma
    • Uka K, Aikata H, Takaki S, et al: Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 2007; 13:414-420.
    • (2007) World J Gastroenterol , vol.13 , pp. 414-420
    • Uka, K.1    Aikata, H.2    Takaki, S.3
  • 15
    • 0034526714 scopus 로고    scopus 로고
    • Advanced hepatocellular carcinoma with distant metastases, successfully treated by a combination therapy of alpha-interferon and oral tegafur/uracil
    • Miyamoto A, Umeshita K, Sakon M, et al: Advanced hepatocellular carcinoma with distant metastases, successfully treated by a combination therapy of alpha-interferon and oral tegafur/uracil. J Gastroenterol Hepatol 2000; 15:1447-1451.
    • (2000) J Gastroenterol Hepatol , vol.15 , pp. 1447-1451
    • Miyamoto, A.1    Umeshita, K.2    Sakon, M.3
  • 16
    • 32944477776 scopus 로고    scopus 로고
    • Complete disappearance of metastatic lung tumors and mediastinal lymphnode in a case of hepatocellular carcinoma treated by low-dose 5-fluorouracil/cisplatin therapy
    • Anami Y, Oguma S, Matsuda Y, et al: Complete disappearance of metastatic lung tumors and mediastinal lymphnode in a case of hepatocellular carcinoma treated by low-dose 5-fluorouracil/cisplatin therapy. Gan To Kagaku Ryoho 2005; 32:1977-1980.
    • (2005) Gan to Kagaku Ryoho , vol.32 , pp. 1977-1980
    • Anami, Y.1    Oguma, S.2    Matsuda, Y.3
  • 17
    • 0037315472 scopus 로고    scopus 로고
    • Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma
    • Patt YZ, Hassan MM, Lozano RD, et al: Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003; 21:421-427.
    • (2003) J Clin Oncol , vol.21 , pp. 421-427
    • Patt, Y.Z.1    Hassan, M.M.2    Lozano, R.D.3
  • 18
    • 13444257368 scopus 로고    scopus 로고
    • A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma
    • Ikeda M, Okusaka T, Ueno H, Takezako Y, Morizane C: A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer 2005; 103:756-762.
    • (2005) Cancer , vol.103 , pp. 756-762
    • Ikeda, M.1    Okusaka, T.2    Ueno, H.3    Takezako, Y.4    Morizane, C.5
  • 19
    • 49849086361 scopus 로고    scopus 로고
    • Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases
    • Uka K, Aikata H, Mori N, et al: Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases. Oncology 2008; 75:8-16.
    • (2008) Oncology , vol.75 , pp. 8-16
    • Uka, K.1    Aikata, H.2    Mori, N.3
  • 20
    • 42149116298 scopus 로고    scopus 로고
    • Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis
    • Nakamura M, Nagano H, Marubashi S, et al: Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis. Cancer 2008; 112:1765-1771.
    • (2008) Cancer , vol.112 , pp. 1765-1771
    • Nakamura, M.1    Nagano, H.2    Marubashi, S.3
  • 21
    • 0029835349 scopus 로고    scopus 로고
    • Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
    • Shirasaka T, Shimamato Y, Ohshimo H, et al: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7:548-557.
    • (1996) Anticancer Drugs , vol.7 , pp. 548-557
    • Shirasaka, T.1    Shimamato, Y.2    Ohshimo, H.3
  • 22
    • 0030942752 scopus 로고    scopus 로고
    • A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein
    • Ando E, Yamashita F, Tanaka M, Tanikawa K: A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997; 79:1890-1896.
    • (1997) Cancer , vol.79 , pp. 1890-1896
    • Ando, E.1    Yamashita, F.2    Tanaka, M.3    Tanikawa, K.4
  • 23
    • 0036682065 scopus 로고    scopus 로고
    • Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: Analysis of 48 cases
    • Ando E, Tanaka M, Yamashita F, et al: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95:588-595.
    • (2002) Cancer , vol.95 , pp. 588-595
    • Ando, E.1    Tanaka, M.2    Yamashita, F.3
  • 24
    • 9144268371 scopus 로고    scopus 로고
    • Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis
    • Lai YC, Shih CY, Jeng CM, et al: Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2003; 9:2666-2670.
    • (2003) World J Gastroenterol , vol.9 , pp. 2666-2670
    • Lai, Y.C.1    Shih, C.Y.2    Jeng, C.M.3
  • 25
    • 0020396015 scopus 로고
    • Toxicity and response criteria of the Eastern Cooperative Oncology Group
    • Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-655.
    • (1982) Am J Clin Oncol , vol.5 , pp. 649-655
    • Oken, M.M.1    Creech, R.H.2    Tormey, D.C.3
  • 26
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors
    • European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 27
    • 33646383886 scopus 로고    scopus 로고
    • Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion
    • Obi S, Yoshida H, Toune R, et al: Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106:1990-1997.
    • (2006) Cancer , vol.106 , pp. 1990-1997
    • Obi, S.1    Yoshida, H.2    Toune, R.3
  • 28
    • 26944439521 scopus 로고    scopus 로고
    • Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression
    • Ota H, Nagano H, Sakon M, et al: Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005; 93:557-564.
    • (2005) Br J Cancer , vol.93 , pp. 557-564
    • Ota, H.1    Nagano, H.2    Sakon, M.3
  • 29
    • 0037080269 scopus 로고    scopus 로고
    • Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches
    • DOI 10.1002/cncr.10246
    • Sakon M, Nagano H, Dono K, et al: Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94:435-442. (Pubitemid 34081374)
    • (2002) Cancer , vol.94 , Issue.2 , pp. 435-442
    • Sakon, M.1    Nagano, H.2    Dono, K.3    Nakamori, S.4    Umeshita, K.5    Yamada, A.6    Kawata, S.7    Imai, Y.8    Iijima, S.9    Monden, M.10
  • 30
    • 35148870112 scopus 로고    scopus 로고
    • Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma
    • Uka K, Aikata H, Takaki S, et al: Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. Liver Int 2007; 27:1209-1216.
    • (2007) Liver Int , vol.27 , pp. 1209-1216
    • Uka, K.1    Aikata, H.2    Takaki, S.3
  • 31
    • 35448994259 scopus 로고    scopus 로고
    • Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma
    • Uka K, Aikata H, Takaki S, et al: Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol 2007; 42:845-853.
    • (2007) J Gastroenterol , vol.42 , pp. 845-853
    • Uka, K.1    Aikata, H.2    Takaki, S.3
  • 32
    • 0022886092 scopus 로고
    • Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma ceUs
    • Scanlon KJ, Newman EM, Lu Y, Priest DG: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma ceUs. Proc Natl Acad Sci U S A 1986; 83:8923-8925.
    • (1986) Proc Natl Acad Sci U S A , vol.83 , pp. 8923-8925
    • Scanlon, K.J.1    Newman, E.M.2    Lu, Y.3    Priest, D.G.4
  • 33
    • 0027285520 scopus 로고
    • Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo
    • Shirasaka T, Shimamoto Y, Ohshimo H, Saito H, Fukushima M: Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993; 32:167-172.
    • (1993) Cancer Chemother Pharmacol , vol.32 , pp. 167-172
    • Shirasaka, T.1    Shimamoto, Y.2    Ohshimo, H.3    Saito, H.4    Fukushima, M.5
  • 34
    • 40749153540 scopus 로고    scopus 로고
    • S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial
    • Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9:215-221.
    • (2008) Lancet Oncol , vol.9 , pp. 215-221
    • Koizumi, W.1    Narahara, H.2    Hara, T.3
  • 35
    • 9744222663 scopus 로고    scopus 로고
    • S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: A multi-institutional phase II trial
    • Ichinose Y, Yoshimori K, Sakai H, et al: S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 2004; 10:7860-7864.
    • (2004) Clin Cancer Res , vol.10 , pp. 7860-7864
    • Ichinose, Y.1    Yoshimori, K.2    Sakai, H.3
  • 36
    • 0034125357 scopus 로고    scopus 로고
    • Induction of thymidine Phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, foUnic acid and interferon alpha
    • Braybrooke JP, Propper DJ, O'Byrne KJ, et al: Induction of thymidine Phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, foUnic acid and interferon alpha. Br J Cancer 2000; 83:219-224.
    • (2000) Br J Cancer , vol.83 , pp. 219-224
    • Braybrooke, J.P.1    Propper, D.J.2    O'Byrne, K.J.3
  • 37
    • 0025293764 scopus 로고
    • Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review
    • Wadler S, Schwartz EL: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990; 50:3473-3486.
    • (1990) Cancer Res , vol.50 , pp. 3473-3486
    • Wadler, S.1    Schwartz, E.L.2
  • 38
    • 63649164307 scopus 로고    scopus 로고
    • Successful treatment of pulmonary metastases associated with advanced hepatocellular carcinoma by systemic 5-fluorouracil combined with interferon-alpha in a hemodialysis patient
    • Katamura Y, Aikata H, Kimura Y, et al: Successful treatment of pulmonary metastases associated with advanced hepatocellular carcinoma by systemic 5-fluorouracil combined with interferon-alpha in a hemodialysis patient. Hepatol Res 2009; 39:415-420.
    • (2009) Hepatol Res , vol.39 , pp. 415-420
    • Katamura, Y.1    Aikata, H.2    Kimura, Y.3
  • 39
    • 67349198077 scopus 로고    scopus 로고
    • Activation of Wnt/beta-catenin signalalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma
    • Noda T, Nagano H, Takemasa I, et al: Activation of Wnt/beta-catenin signalalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer 2009; 100:1647-1658.
    • (2009) Br J Cancer , vol.100 , pp. 1647-1658
    • Noda, T.1    Nagano, H.2    Takemasa, I.3
  • 40
    • 1642375906 scopus 로고    scopus 로고
    • The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatoceUular carcinoma and its predictable factors
    • Kogure T, Ueno Y, Iwasaki T, Shimosegawa T: The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatoceUular carcinoma and its predictable factors. Cancer Chemother Pharmacol 2004; 53:296-304.
    • (2004) Cancer Chemother Pharmacol , vol.53 , pp. 296-304
    • Kogure, T.1    Ueno, Y.2    Iwasaki, T.3    Shimosegawa, T.4
  • 41
    • 0032837081 scopus 로고    scopus 로고
    • Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves
    • Nishiyama M, Yamamoto W, Park JS, et al: Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 1999; 5:2620-2628.
    • (1999) Clin Cancer Res , vol.5 , pp. 2620-2628
    • Nishiyama, M.1    Yamamoto, W.2    Park, J.S.3
  • 42
    • 47949116252 scopus 로고    scopus 로고
    • Sorafenib in advanced hepatocellular carcinoma
    • Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
    • (2008) N Engl J Med , vol.359 , pp. 378-390
    • Llovet, J.M.1    Ricci, S.2    Mazzaferro, V.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.